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663Abstracts
Cumulative incidences of ESRD were 54.7%, 59.3% and
46.7% for control, amlodipine, and irbesartan respec-
tively.When a 25-year (lifetime) horizon was considered,
delay in ESRD onset led to anticipated improvements in
life expectancy (discounted results shown in brackets) of
0.29 (0.15) years versus amlodipine and 0.63 (0.36) years
versus control. Irbesartan led to cost savings of Hun-
garian Forint (HUF) 2,698,826 (€10,267) and HUF
1,605,897 (€6,109) per patient versus amlodipine and
control respectively. The results were robust under a wide
range of plausible assumptions. CONCLUSIONS: Treat-
ing patients with hypertension, type 2 diabetes and overt
nephropathy using irbesartan was both cost- and life-
saving compared to amlodipine and control in the 
Hungarian setting.
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OBJECTIVE: More than 5.4 million Russian patients
have an history of Ischemic Heart Disease and this
accounts for 26% of all deaths every year. The CURE 
trial demonstrated the efﬁcacy of clopidogrel in ACS, vs
placebo, both group received standard therapy including
ASA. This evaluation was performed to assess the cost-
effectiveness of clopidogrel in Russia based upon the
CURE trial. METHODS: Resource use (hospitalisations,
procedures, comedications, study drugs) was collected in
the Case Report Form of the clinical trial. Costs of med-
ications were based on cost per day of study drugs and
average cost per day of the different therapeutic classes
for comedications. Hospitalisations costs including the
costs of stay at an intensive care unit were calculated 
from Russian medicoeconomic standards. The efﬁcacy
outcome was the number of total events prevented (car-
diovascular deaths, myocardial infarctions, and strokes).
Cost-effectiveness was expressed as the cost per event
avoided with clopidogrel plus ASA versus ASA alone. All
costs were calculated in 2002 prices. The Russian ruble-
to-US dollar exchange rate used was 31.3. RESULTS:
During the 12-month study period, the CURE trial
showed that patients treated with clopidogrel had signif-
icantly lower rates of cardiovascular events (11.14% vs
13.15%). The mean cost per patient was higher with
clopidogrel ($2,425.60) than with standard therapy
($18,82.80). The difference of $542.80 was primarily due
to a higher acquisition cost of clopidogrel. Nevertheless
total cost of hospitalisations was lower in the clopidogrel
arm ($1119 vs $1149). The estimated incremental cost
per event avoided was $27,000. CONCLUSION: This
analysis showed that clopidogrel on top of standard
therapy including ASA, for ACS, results in a favourable
cost-effectiveness ratio in terms the cost per event avoided
compared to other cardiovascular drugs. These data
provide strong arguments for the choice of a treatment
for ACS in the public health care system.
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OBJECTIVES: The Clinical Decision Support Systems
(CDSS) can be intended as tools to improve the health
care. The Optimcare Study objectives are to implement a
clinical guideline to manage hypercholesterolemic patients
on a CDSS and to assess its impact in cost-effectiveness
terms, in usual practice conditions. METHODS:
Naturalistic and unicentric design in which a therapeuti-
cally intervention including a CDSS and a ﬂexible patient
education was applied and compared between two periods
in a patient cohort. Five hundred hypercholesterolemic
patients (ICD9-CM code = 272.0) were randomiously
selected from the Primary Health Care center database
(CAP Vila Olímpica, Barcelona, Spain). The CDSS imple-
mented algorithms agreed by the participating physicians,
with therapeutical recommendations to achieve cLDL
objectives in a cost-effective manner. The compared
periods were the year before (PRE) and the year after (POS)
the ﬁrst visit in which physicians could access to the CDSS
from their physician desk. The clinical and resources con-
sumption data in PRE were obtained from the center data-
base. The effectiveness was assessed through the
therapeutical objective achievement in PRE and POS
periods referred to the clinical guideline objectives. The
costs were assessed from the social perspective. RESULTS:
The therapeutical objective achievement increased an
11.9% (54,2% PRE vs 66.1% POS). While cLDL
decreased 10mg/dl (CI 95% -14 to -6). The number of
pharmacologically treated patients decreased a 14.6%
(76.5% PRE vs 61.9% POS). The patient mean total costs
were decreased in POS period [difference = €78.4 (IC 95%
-94.7 to -62.1)]. Considering all the visits the adherence
to the therapeutical recommendations were a 88.4% while
showed a decrease until 72.5% when next visit dates rec-
ommendations were considered. CONCLUSIONS: The
CDSS given recommendations were accepted by the 
physician in a high degree and were shown as more cost-
effective than the usual care practice.
